SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is capturing market attention as its annual GTC conference kicks off, with investors closely watching for the unveiling of next-generation AI architecture and strategic partnerships. The community is actively debating the sustainability of AI infrastructure spending and the potential for a 'sell the news' reaction, despite excitement surrounding massive new enterprise integration deals.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is currently capturing attention as traders debate the potential impact of the proposed CLARITY Act and its role in fostering institutional adoption despite ongoing price volatility. While some community members remain deeply skeptical of market manipulation and the project's long-term utility, others view current price movements as an accumulation opportunity driven by growing international integration and anticipation of future regulatory milestones.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending as the community debates a series of strategic developments, most notably the integration of Intel Xeon 6 processors into Nvidia's DGX Rubin NVL8 systems. While some investors are optimistic that these high-profile partnerships and foundry expansion signals a long-term turnaround, others remain cautious, citing bearish options flow and persistent market volatility.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics Inc

CytomX Therapeutics is experiencing high-volume momentum and significant volatility following a positive clinical data update for its late-line colorectal cancer program, Varseta-M. Investors are heavily focused on the stock's potential for near-term catalysts, with community sentiment split between enthusiasm for its pipeline progress and caution regarding potential future dilution or earnings-related volatility.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is driving intense investor debate as it aggressively expands its Ethereum treasury, now holding 3.81% of the total ETH supply and leading a new $125 million funding round for Eightco Holdings. While bullish community members point to the company's massive ETH accumulation, staking revenue, and strategic AI partnerships as signs of long-term value, critics frequently voice concerns over ongoing share dilution and the stock's tendency to lag behind broader crypto market rallies.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp is surging as investors react to a combination of its upcoming NYSE uplisting, a significant government defense contract award, and high-profile media appearances by CEO Gary Evans. The community is heavily focused on the company's potential to capitalize on the growing demand for critical minerals like antimony and tungsten amid ongoing supply chain concerns and geopolitical tensions.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

Better Home & Finance is currently experiencing significant downward volatility and high trading volume as investors react to the unwinding of previous speculative momentum and broader concerns across the mortgage sector. While the community remains deeply divided, active discussions are focused on the company's long-term potential for AI-driven mortgage origination via its Tinman platform, with some investors accumulating positions at lower price points in anticipation of future partnership announcements and institutional scaling.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending as investors react to the companys recent operational updates, specifically the increased patient screening rates for its FLAMINGO-01 Phase 3 trial and the FDA approval of commercially manufactured GP2 vials. The community is focused on the strategic endorsement of the trials Steering Committee, which is co-authoring upcoming AACR abstracts, and remains heavily invested in the potential for an interim data readout to act as a major catalyst for a valuation re-rating.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant volatility driven by high short interest and speculative chatter regarding a potential short squeeze, while investors continue to monitor its edge-based "Agentic AI" platform demonstrations at NVIDIA GTC. The community remains deeply polarized, with bulls pointing to robust revenue growth and major industry partnerships as indicators of long-term upside, while bears express frustration over the stock's persistent downward trend and lack of immediate catalysts to break out of its current range.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

Geo Group is trending as investors weigh strong quarterly revenue and earnings beats against concerns about the pace of detention facility activations and potential political headwinds. The community is actively discussing the company's increased share buyback authorization while closely monitoring how DHS funding and potential policy shifts under the new administration will impact future contract opportunities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Anixa Biosciences (NASDAQ:ANIX) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen lowered shares of Anixa Biosciences from a "hold" rating to a "sell" rating in a research report on Sunday...

Anixa Biosciences AGM: Shareholders Back Directors as CEO Highlights CAR-T, Vaccine Progress

Anixa Biosciences (NASDAQ:ANIX) held its 2026 Annual Meeting of Stockholders via live webcast, outlining the results of shareholder votes and providing an operational update focused on the company's...

Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast

Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast PR Newswire SAN JOSE, Calif., March...

Anixa Biosciences (NASDAQ:ANIX) Posts Earnings Results, Beats Expectations By $0.01 EPS

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.01...

Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology Anixa Biosciences Receives Notice of Allowance...

Anixa Biosciences (NASDAQ:ANIX) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded Anixa Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday...

Anixa Biosciences (ANIX) to Release Earnings on Tuesday

Anixa Biosciences (NASDAQ:ANIX) will be releasing its Q1 2026 earnings before the market opens on Tuesday, March 10. (View Earnings Report at...

Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress

Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress Anixa Biosciences to Host 2026 Annual Meeting of...

Anixa Biosciences Inc (NASDAQ:ANIX) Given Average Recommendation of "Hold" by Analysts

Shares of Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) have been assigned an average recommendation of "Hold" from the five brokerages that are covering the company, MarketBeat.com reports...

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat Anixa Biosciences Announces Dr. Jose Conejo-Garcia will...

Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology. It operates through the following segments: Cancer Vaccines, CAR-T Therapeutics, and Other. The Cancer Vaccines segment includes the early stages development of immunization for breast and ovarian cancer. The CAR-T Therapeutics segment is involved in the development of immuno-therapy drugs against cancer. The Other segment refers to its legacy operations, including patent licensing. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Current Price	$2.90
Prev Close	$2.83
Open	$2.84
Dividend Yield	0.00%
50-Day Moving Average	$3.03
Beta	1.15
Avg. Volume	148,238.49
PE Ratio	-8.98

52-Week High	$5.46
52-Week Low	$2.33
Market Capitalization	$94.88M
EPS (Annual)	-$0.3367
Price to Book	6.28
Revenue Per Employee	$0.00

ANIX
Anixa Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ANIX News

ANIXAnixa Biosciences Inc